Trial · NCT00260962
Olanzapine in the Treatment of Patients With Anorexia Nervosa
NCT00260962, Phase 2, Completed, Ottawa Hospital Research Institute; results first posted 2017-04-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Olanzapine in the Treatment of Patients With Anorexia Nervosa. Trials, record NCT00260962. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00260962
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Olanzapine in the Treatment of Patients With Anorexia Nervosa
- NCT number
- NCT00260962
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 34 participants, actual
- Lead sponsor
- Ottawa Hospital Research Institute
- Conditions
- Anorexia Nervosa
- Interventions
- Olanzapine, Day Hospital
- First posted
- 2005-12-02
- Last updated
- 2018-01-30
- Results first posted
- 2017-04-28
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Body Mass Index (BMI) (kg/m^2) | Baseline (week 2) and post-treatment (week 13) | Body Mass Index (BMI) measured in kg/m\^2 units. Measured at Baseline (week 2) and post-treatment (week 13). |
| Secondary | Obsessions | Pretreatment (Week 1) and Posttreatment (Week 13) | Obsessions subscale of the Yale-Brown Obsessive Compulsive Scale. Minimum score is 0 and maximum score is 20. Higher scores indicate higher levels of obsessions. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Body Mass Index (BMI) (kg/m^2) | Baseline (week 2) and post-treatment (week 13) | 4 participants discontinued in placebo group and 2 did not have weight measurements at week 13. 2 participants discontinued in the olanzapine group | kg/m^2 | MEAN |
| SECONDARY | Obsessions | Pretreatment (Week 1) and Posttreatment (Week 13) | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Body Mass Index (BMI) (kg/m^2) | Placebo Plus Day Hospital | Week 2 baseline | 19.66 | Standard Deviation 1.32 | kg/m^2 |
| Body Mass Index (BMI) (kg/m^2) | Olanzapine Plus Day Hospital | Week 2 baseline | 20.30 | Standard Deviation 0.99 | kg/m^2 |
| Body Mass Index (BMI) (kg/m^2) | Placebo Plus Day Hospital | Week 13 | 19.66 | Standard Deviation 1.32 | kg/m^2 |
| Body Mass Index (BMI) (kg/m^2) | Olanzapine Plus Day Hospital | Week 13 | 20.30 | Standard Deviation 0.99 | kg/m^2 |
| Obsessions | Placebo Plus Day Hospital | Pretreatment | 9.11 | Standard Deviation 5.58 | units on a scale |
| Obsessions | Olanzapine Plus Day Hospital | Pretreatment | 11.06 | Standard Deviation 3.96 | units on a scale |
| Obsessions | Placebo Plus Day Hospital | Posttreatment | 5.86 | Standard Deviation 4.83 | units on a scale |
| Obsessions | Olanzapine Plus Day Hospital | Posttreatment | 6.54 | Standard Deviation 4.29 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo Plus Day Hospital | 18 | |
| Overall Study | STARTED | Olanzapine Plus Day Hospital | 16 | |
| Overall Study | COMPLETED | Placebo Plus Day Hospital | 14 | |
| Overall Study | COMPLETED | Olanzapine Plus Day Hospital | 14 | |
| Overall Study | NOT COMPLETED | Placebo Plus Day Hospital | 4 | |
| Overall Study | NOT COMPLETED | Olanzapine Plus Day Hospital | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo Plus Day Hospital | ||
| Total, all-cause mortality | Olanzapine Plus Day Hospital | ||
| Total, other adverse events | Placebo Plus Day Hospital | 0 | 18 |
| Total, other adverse events | Olanzapine Plus Day Hospital | 0 | 16 |
| Total, serious adverse events | Placebo Plus Day Hospital | 0 | 18 |
| Total, serious adverse events | Olanzapine Plus Day Hospital | 0 | 16 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 18558642 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Placebo Plus Day Hospital vs Olanzapine Plus Day Hospital: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00260962
GET https://conductscience.org/api/trials/v1/NCT00260962/registered